5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Myelosuppression O
, O
Immunosuppression O
, O
Bone O
Marrow O
Failure O
and O
Infections O
- O
Severe O
immunosuppression O
may O
lead O
to O
serious O
and O
sometimes O
fatal O
infections O
. O

Close O
hematological O
monitoring O
is O
required O
. O

( O
5.1 O
) O
* O
Urinary O
Tract O
and O
Renal O
Toxicity O
- O
Hemorrhagic O
cystitis O
, O
pyelitis O
, O
ureteritis O
, O
and O
hematuria O
can O
occur O
. O

Exclude O
or O
correct O
any O
urinary O
tract O
obstructions O
prior O
to O
treatment O
. O

( O
5.2 O
) O
* O
Cardiotoxicity O
- O
Myocarditis O
, O
myopericarditis O
, O
pericardial O
effusion O
, O
arrythmias O
and O
congestive O
heart O
failure O
, O
which O
may O
be O
fatal O
, O
have O
been O
reported O
. O

Monitor O
patients O
, O
especially O
those O
with O
risk O
factors O
for O
cardiotoxicity O
or O
pre-existing O
cardiac O
disease O
. O

( O
5.3 O
) O
* O
Pulmonary O
Toxicity O
- O
Pneumonitis O
, O
pulmonary O
fibrosis O
and O
pulmonary O
veno-occlusive O
disease O
leading O
to O
respiratory O
failure O
may O
occur O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
of O
pulmonary O
toxicity O
. O

( O
5.4 O
) O
* O
Secondary O
malignancies O
( O
5.5 O
) O
* O
Veno-occlusive O
Liver O
Disease O
- O
Fatal O
outcome O
can O
occur O
. O

( O
5.6 O
) O
* O
Embryo-Fetal O
Toxicity O
- O
Can O
cause O
fetal O
harm O
. O

Advise O
female O
patients O
of O
reproductive O
potential O
to O
avoid O
pregnancy O
. O

( O
5.7 O
, O
8.1 O
, O
8.6 O
) O
5.1 O
Myelosuppression O
, O
Immunosuppression O
, O
Bone O
Marrow O
Failure O
and O
Infections O
Cyclophosphamide O
can O
cause O
myelosuppression B-OSE_Labeled_AE
( O
leukopenia B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
and O
anemia B-OSE_Labeled_AE
) O
, O
bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
and O
severe O
immunosuppression B-OSE_Labeled_AE
which O
may O
lead O
to O
serious O
and O
sometimes O
fatal B-NonOSE_AE
infections B-NonOSE_AE
, O
including O
sepsis B-NonOSE_AE
and O
septic B-NonOSE_AE
shock I-NonOSE_AE
. O

Latent B-OSE_Labeled_AE
infections I-OSE_Labeled_AE
can I-OSE_Labeled_AE
be I-OSE_Labeled_AE
reactivated I-OSE_Labeled_AE
[ O
see O
Adverse O
Reactions O
( O
6.2 O
) O
] O
. O

Antimicrobial O
prophylaxis O
may O
be O
indicated O
in O
certain O
cases O
of O
neutropenia B-NonOSE_AE
at O
the O
discretion O
of O
the O
managing O
physician O
. O

In O
case O
of O
neutropenic B-NonOSE_AE
fever I-NonOSE_AE
, O
antibiotic O
therapy O
is O
indicated O
. O

Antimycotics O
and/or O
antivirals O
may O
also O
be O
indicated O
. O

Monitoring O
of O
complete O
blood O
counts O
is O
essential O
during O
cyclophosphamide O
treatment O
so O
that O
the O
dose O
can O
be O
adjusted O
, O
if O
needed O
. O

Cyclophosphamide O
should O
not O
be O
administered O
to O
patients O
with O
neutrophils B-Not_AE_Candidate
< I-Not_AE_Candidate
= I-Not_AE_Candidate
1 I-Not_AE_Candidate
, I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
and O
platelets B-Not_AE_Candidate
< I-Not_AE_Candidate
5 I-Not_AE_Candidate
0 I-Not_AE_Candidate
, I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
/ I-Not_AE_Candidate
mm I-Not_AE_Candidate
3 I-Not_AE_Candidate
. O

Cyclophosphamide O
treatment O
may O
not O
be O
indicated O
, O
or O
should O
be O
interrupted O
, O
or O
the O
dose O
reduced O
, O
in O
patients O
who O
have O
or O
who O
develop O
a O
serious O
infection B-NonOSE_AE
. O

G-CSF O
may O
be O
administered O
to O
reduce O
the O
risks O
of O
neutropenia B-NonOSE_AE
complications O
associated O
with O
cyclophosphamide O
use O
. O

Primary O
and O
secondary O
prophylaxis O
with O
G-CSF O
should O
be O
considered O
in O
all O
patients O
considered O
to O
be O
at O
increased O
risk O
for O
neutropenia B-NonOSE_AE
complications O
. O

The O
nadirs O
of O
the O
reduction B-NonOSE_AE
in I-NonOSE_AE
leukocyte I-NonOSE_AE
count I-NonOSE_AE
and O
thrombocyte O
count O
are O
usually O
reached O
in O
weeks O
1 O
and O
2 O
of O
treatment O
. O

Peripheral O
blood O
cell O
counts O
are O
expected O
to O
normalize O
after O
approximately O
20 O
days O
. O

Bone B-OSE_Labeled_AE
marrow I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
has O
been O
reported O
. O

Severe O
myelosuppression B-NonOSE_AE
may O
be O
expected O
particularly O
in O
patients O
pretreated O
with O
and/or O
receiving O
concomitant O
chemotherapy O
and/or O
radiation O
therapy O
. O

5.2 O
Urinary O
Tract O
and O
Renal O
Toxicity O
Hemorrhagic B-OSE_Labeled_AE
cystitis I-OSE_Labeled_AE
, O
pyelitis B-OSE_Labeled_AE
, O
ureteritis B-OSE_Labeled_AE
, O
and O
hematuria B-OSE_Labeled_AE
have O
been O
reported O
with O
cyclophosphamide O
. O

Medical O
and/or O
surgical O
supportive O
treatment O
may O
be O
required O
to O
treat O
protracted O
cases O
of O
severe O
hemorrhagic B-NonOSE_AE
cystitis I-NonOSE_AE
. O

Discontinue O
cyclophosphamide O
therapy O
in O
case O
of O
severe O
hemorrhagic B-NonOSE_AE
cystitis I-NonOSE_AE
. O

Urotoxicity B-NonOSE_AE
( O
bladder B-NonOSE_AE
ulceration I-NonOSE_AE
, O
necrosis O
, O
fibrosis O
, O
contracture O
and O
secondary O
cancer O
) O
may O
require O
interruption O
of O
cyclophosphamide O
treatment O
or O
cystectomy O
. O

Urotoxicity B-NonOSE_AE
can O
be O
fatal B-NonOSE_AE
. O

Urotoxicity B-OSE_Labeled_AE
can O
occur O
with O
short-term O
or O
long-term O
use O
of O
cyclophosphamide O
. O

Before O
starting O
treatment O
, O
exclude O
or O
correct O
any O
urinary B-Not_AE_Candidate
tract I-Not_AE_Candidate
obstructions I-Not_AE_Candidate
[ O
see O
Contraindications O
( O
4 O
) O
] O
. O

Urinary O
sediment O
should O
be O
checked O
regularly O
for O
the O
presence O
of O
erythrocytes O
and O
other O
signs O
of O
urotoxicity B-NonOSE_AE
and/or O
nephrotoxicity B-NonOSE_AE
. O

Cyclophosphamide O
should O
be O
used O
with O
caution O
, O
if O
at O
all O
, O
in O
patients O
with O
active O
urinary B-Not_AE_Candidate
tract I-Not_AE_Candidate
infections I-Not_AE_Candidate
. O

Aggressive O
hydration O
with O
forced O
diuresis B-NonOSE_AE
and O
frequent O
bladder B-NonOSE_AE
emptying I-NonOSE_AE
can O
reduce O
the O
frequency O
and O
severity O
of O
bladder B-NonOSE_AE
toxicity I-NonOSE_AE
. O

Mesna O
has O
been O
used O
to O
prevent O
severe O
bladder B-NonOSE_AE
toxicity I-NonOSE_AE
. O

5.3 O
Cardiotoxicity O
Myocarditis B-OSE_Labeled_AE
, O
myopericarditis B-OSE_Labeled_AE
, O
pericardial B-OSE_Labeled_AE
effusion I-OSE_Labeled_AE
including O
cardiac B-OSE_Labeled_AE
tamponade I-OSE_Labeled_AE
, O
and O
congestive B-OSE_Labeled_AE
heart I-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
which O
may O
be O
fatal B-NonOSE_AE
, O
have O
been O
reported O
with O
cyclophosphamide O
therapy O
Supraventricular B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
( O
including O
atrial B-OSE_Labeled_AE
fibrillation O
and O
flutter I-OSE_Labeled_AE
) O
and O
ventricular B-OSE_Labeled_AE
arrhythmias I-OSE_Labeled_AE
( O
including O
severe O
QT B-OSE_Labeled_AE
prolongation I-OSE_Labeled_AE
associated O
with O
ventricular B-OSE_Labeled_AE
tachyarrhythmia I-OSE_Labeled_AE
) O
have O
been O
reported O
after O
treatment O
with O
regimens O
that O
included O
cyclophosphamide O
. O

The O
risk O
of O
cardiotoxicity B-OSE_Labeled_AE
may O
be O
increased O
with O
high O
doses O
of O
cyclophosphamide O
, O
in O
patients O
with O
advanced O
age O
, O
and O
in O
patients O
with O
previous O
radiation O
treatment O
to O
the O
cardiac O
region O
and/or O
previous O
or O
concomitant O
treatment O
with O
other O
cardiotoxic B-NonOSE_AE
agents I-NonOSE_AE
. O

Particular O
caution O
is O
necessary O
in O
patients O
with O
risk O
factors O
for O
cardiotoxicity B-NonOSE_AE
and O
in O
patients O
with O
pre-existing O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

Monitor O
patients O
with O
risk O
factors O
for O
cardiotoxicity B-NonOSE_AE
and O
with O
pre-existing O
cardiac B-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

5.4 O
Pulmonary O
Toxicity O
Pneumonitis B-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
fibrosis I-OSE_Labeled_AE
, O
pulmonary B-OSE_Labeled_AE
veno I-OSE_Labeled_AE
- I-OSE_Labeled_AE
occlusive I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
and O
other O
forms O
of O
pulmonary B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
leading O
to O
respiratory B-NonOSE_AE
failure I-NonOSE_AE
have O
been O
reported O
during O
and O
following O
treatment O
with O
cyclophosphamide O
. O

Late O
onset O
pneumonitis B-NonOSE_AE
( O
greater O
than O
6 O
months O
after O
start O
of O
cyclophosphamide O
) O
appears O
to O
be O
associated O
with O
increased O
mortality B-NonOSE_AE
. O

Pneumonitis B-OSE_Labeled_AE
may O
develop O
years O
after O
treatment O
with O
cyclophosphamide O
. O

Monitor O
patients O
for O
signs O
and O
symptoms O
of O
pulmonary B-NonOSE_AE
toxicity I-NonOSE_AE
. O

5.5 O
Secondary O
Malignancies O
Cyclophosphamide O
is O
genotoxic B-OSE_Labeled_AE
[ O
see O
Nonclinical O
Toxicology O
( O
13.1 O
) O
] O
. O

Secondary B-OSE_Labeled_AE
malignancies I-OSE_Labeled_AE
( O
urinary B-OSE_Labeled_AE
tract I-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
myelodysplasia B-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
leukemias I-OSE_Labeled_AE
, O
lymphomas B-OSE_Labeled_AE
, O
thyroid B-OSE_Labeled_AE
cancer I-OSE_Labeled_AE
, O
and O
sarcomas B-OSE_Labeled_AE
) O
have O
been O
reported O
in O
patients O
treated O
with O
cyclophosphamide-containing O
regimens O
. O

The O
risk O
of O
bladder B-NonOSE_AE
cancer I-NonOSE_AE
may O
be O
reduced O
by O
prevention O
of O
hemorrhagic B-NonOSE_AE
cystitis I-NonOSE_AE
. O

5.6 O
Veno-occlusive O
Liver O
Disease O
Veno B-OSE_Labeled_AE
- I-OSE_Labeled_AE
occlusive I-OSE_Labeled_AE
liver I-OSE_Labeled_AE
disease I-OSE_Labeled_AE
( I-OSE_Labeled_AE
VOD I-OSE_Labeled_AE
) O
including O
fatal B-NonOSE_AE
outcome O
has O
been O
reported O
in O
patients O
receiving O
cyclophosphamide-containing O
regimens O
. O

A O
cytoreductive O
regimen O
in O
preparation O
for O
bone B-Not_AE_Candidate
marrow I-Not_AE_Candidate
transplantation I-Not_AE_Candidate
that O
consists O
of O
cyclophosphamide O
in O
combination O
with O
whole-body O
irradiation O
, O
busulfan O
, O
or O
other O
agents O
has O
been O
identified O
as O
a O
major O
risk O
factor O
. O

VOD B-OSE_Labeled_AE
has O
also O
been O
reported O
to O
develop O
gradually O
in O
patients O
receiving O
long-term O
low-dose O
immunosuppressive B-NonOSE_AE
doses O
of O
cyclophosphamide O
. O

Other O
risk O
factors O
predisposing O
to O
the O
development O
of O
VOD B-NonOSE_AE
include O
preexisting O
disturbances B-Not_AE_Candidate
of I-Not_AE_Candidate
hepatic I-Not_AE_Candidate
function I-Not_AE_Candidate
, O
previous O
radiation O
therapy O
of O
the O
abdomen O
, O
and O
a O
low O
performance O
status O
. O

5.7 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Cyclophosphamide O
can O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
administered O
to O
a O
pregnant B-Not_AE_Candidate
woman O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

Exposure O
to O
cyclophosphamide O
during O
pregnancy B-Not_AE_Candidate
may O
cause O
birth B-OSE_Labeled_AE
defects I-OSE_Labeled_AE
, O
miscarriage B-OSE_Labeled_AE
, O
fetal B-OSE_Labeled_AE
growth I-OSE_Labeled_AE
retardation I-OSE_Labeled_AE
, O
and O
fetotoxic B-OSE_Labeled_AE
effects I-OSE_Labeled_AE
in O
the O
newborn O
. O

Cyclophosphamide O
is O
teratogenic B-NonOSE_AE
and O
embryo B-NonOSE_AE
- I-NonOSE_AE
fetal I-NonOSE_AE
toxic I-NonOSE_AE
in O
mice O
, O
rats O
, O
rabbits O
and O
monkeys O
. O

Advise O
female O
patients O
of O
reproductive O
potential O
to O
avoid O
becoming O
pregnant B-NonOSE_AE
and O
to O
use O
highly O
effective O
contraception O
during O
treatment O
and O
for O
up O
to O
1 O
year O
after O
completion O
of O
therapy O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
] O
. O

5.8 O
Infertility O
Male B-OSE_Labeled_AE
and O
female O
reproductive I-OSE_Labeled_AE
function I-OSE_Labeled_AE
and O
fertility O
may O
be O
impaired I-OSE_Labeled_AE
in O
patients O
being O
treated O
with O
cyclophosphamide O
. O

Cyclophosphamide O
interferes B-OSE_Labeled_AE
with I-OSE_Labeled_AE
oogenesis I-OSE_Labeled_AE
and O
spermatogenesis O
. O

It O
may O
cause O
sterility B-OSE_Labeled_AE
in O
both O
sexes O
. O

Development O
of O
sterility B-NonOSE_AE
appears O
to O
depend O
on O
the O
dose O
of O
cyclophosphamide O
, O
duration O
of O
therapy O
, O
and O
the O
state O
of O
gonadal O
function O
at O
the O
time O
of O
treatment O
. O

Cyclophosphamide B-NonOSE_AE
- I-NonOSE_AE
induced I-NonOSE_AE
sterility I-NonOSE_AE
may O
be O
irreversible O
in O
some O
patients O
. O

Advise O
patients O
on O
the O
potential O
risks O
for O
infertility B-NonOSE_AE
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.4 O
and O
8.6 O
) O
] O
. O

5.9 O
Impairment O
of O
Wound O
Healing O
Cyclophosphamide O
may O
interfere B-OSE_Labeled_AE
with I-OSE_Labeled_AE
normal I-OSE_Labeled_AE
wound I-OSE_Labeled_AE
healing I-OSE_Labeled_AE
. O

5.10 O
Hyponatremia O
Hyponatremia B-OSE_Labeled_AE
associated O
with O
increased B-OSE_Labeled_AE
total I-OSE_Labeled_AE
body I-OSE_Labeled_AE
water I-OSE_Labeled_AE
, O
acute B-OSE_Labeled_AE
water I-OSE_Labeled_AE
intoxication I-OSE_Labeled_AE
, O
and O
a O
syndrome B-OSE_Labeled_AE
resembling I-OSE_Labeled_AE
SIADH I-OSE_Labeled_AE
( I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
of I-OSE_Labeled_AE
inappropriate I-OSE_Labeled_AE
secretion I-OSE_Labeled_AE
of I-OSE_Labeled_AE
antidiuretic I-OSE_Labeled_AE
hormone I-OSE_Labeled_AE
) O
, O
which O
may O
be O
fatal B-NonOSE_AE
, O
has O
been O
reported O
. O

